Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint | Translational Science With Clinical Promise

Translating Drugs From Animals to Humans Do We Need to Prove Efficacy?

Marco A. Zarbin, MD, PhD1
[+] Author Affiliations
1Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, New Jersey
JAMA Ophthalmol. 2014;132(6):667-668. doi:10.1001/jamaophthalmol.2014.882.
Text Size: A A A
Published online


In 2010, DiMasi et al1 analyzed clinical approval success rates and clinical phase transition analyses for the investigational compounds that entered clinical testing between 1999 and 2004 with confidential data from the 50 largest pharmaceutical firms. Only 16% of compounds entering clinical testing eventually gained marketing approval. Most failures occurred in phase 2 and 3 trials, which is not surprising because phase 1 trials are focused on screening for safety and dosing, whereas phase 2 trials focus on establishing efficacy and phase 3 trials focus on confirming safety and efficacy. In view of the fact that the decision to test a compound in clinical trials involves extensive consultation among experienced scientists and clinicians, an overall 84% failure rate (from phase 1 to new drug application approval) seems remarkably high. Some direct consequences of this high failure rate are reduced output of new treatments for our patients and a higher cost of pharmaceutical and biological agents. (The profits from 1 successful compound must cover the losses incurred from 5 failures.) Because funding for medical care is increasingly constrained, an indirect consequence of this failure rate also may be reduced reimbursement for physician services and reduced access to care. Thus, improving the efficiency of product development is a matter of great importance.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Collections